晚期左右半结肠癌中医证候类型差异的研究探讨
Research and Discussion on the Differences in TCM Syndrome Types between Left- and Right-Sided Colon Cancer in Advanced Stages
DOI: 10.12677/tcm.2024.1312495, PDF,   
作者: 吴德柳：成都中医药大学临床医学院，四川 成都；熊绍权*：成都中医药大学附属医院肿瘤一科，四川 成都
关键词: 左右半结肠；中医证型；差异性；综述；Left and Right Colon； Traditional Chinese Medicine Syndrome Type； Difference； Review
摘要: 在消化道恶性肿瘤中，结肠癌颇为常见，根据肿瘤原发部位的不同，分为左右半结肠癌，这两者在流行病学特性、分子生物学特性、临床表现、基因检测结果及治疗预后等多个维度上均存在差异。中医方面左右半结肠癌也存在一定的差异。遵循“方从法出，法随证立”的原则，在选用方剂与药物时，左右半结肠癌展现出特定的用药区别。通过归纳其内在规律并深入剖析左右结肠癌在中医证候类型上的差异，为个体化治疗提供新思路。
Abstract: Among malignant tumors of the digestive tract, colon cancer is relatively common. Based on the primary site of the tumor, it is classified into right-sided and left-sided colon cancer, which differ in various dimensions such as epidemiological characteristics, molecular biological features, clinical manifestations, genetic testing results, and treatment prognosis. There are also certain differences between right-sided and left-sided colon cancer in Traditional Chinese Medicine (TCM). Following the principle of “prescriptions derived from treatment methods, and treatment methods established according to syndromes,” specific medication differences emerge in the selection of prescriptions and herbs in right-sided and left-sided colon cancer. By summarizing the underlying patterns and deeply analyzing the differences in TCM syndrome types between right-sided and left-sided colon cancer, new ideas for individualized treatment can be provided.
文章引用：吴德柳, 熊绍权. 晚期左右半结肠癌中医证候类型差异的研究探讨[J]. 中医学, 2024, 13(12): 3327-3332. https://doi.org/10.12677/tcm.2024.1312495

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Fidler, M.M., Soerjomataram, I. and Bray, F. (2016) A Global View on Cancer Incidence and National Levels of the Human Development Index. International Journal of Cancer, 139, 2436-2446. [Google Scholar] [CrossRef] [PubMed]
[3] 陈功. 2017版美国国立综合癌症网络结直肠癌指南更新解读[J]. 中华胃肠外科杂志, 2017, 20(1): 28-33.
[4] Yahagi, M., Okabayashi, K., Hasegawa, H., Tsuruta, M. and Kitagawa, Y. (2016) The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal Surgery, 20, 648-655. [Google Scholar] [CrossRef] [PubMed]
[5] 龚璐天, 宋卓, 谷珊珊, 等. 结肠癌从左升右降论治思路探析[J]. 中华中医药杂志, 2023, 38(2): 576-579.
[6] 钟敏儿, 吴斌. 左、右半结直肠癌差异性研究进展[J]. 中国医学科学院学报, 2021, 43(6): 980-985.
[7] Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C.H., et al. (2011) Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer. Cancer, 117, 4623-4632. [Google Scholar] [CrossRef] [PubMed]
[8] Benedix, F., Kube, R., Meyer, F., Schmidt, U., Gastinger, I. and Lippert, H. (2010) Comparison of 17,641 Patients with Right and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival. Diseases of the Colon & Rectum, 53, 57-64. [Google Scholar] [CrossRef] [PubMed]
[9] 胡继霖, 卢云. 左、右半结肠癌的差异[J]. 中华结直肠疾病电子杂志, 2018, 7(6): 514-517.
[10] 韩婷婷, 刘馨, 王晓雄, 等. 左、右半结肠癌患者分子生物学与临床病理特征分析[J]. 重庆医学, 2024, 53(7): 1016-1020+1026.
[11] 顾艳宏, 姜争, 李健, 等. 结直肠癌靶向治疗中国专家共识[J]. 中华普通外科学文献(电子版), 2023, 17(1): 1-8.
[12] Van Cutsem, E., Köhne, C., Láng, I., Folprecht, G., Nowacki, M.P., Cascinu, S., et al. (2011) Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival according to Tumor KRAS and BRAF Mutation Status. Journal of Clinical Oncology, 29, 2011-2019. [Google Scholar] [CrossRef] [PubMed]
[13] Qin, S., Li, J., Wang, L., Xu, J., Cheng, Y., Bai, Y., et al. (2018) Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. Journal of Clinical Oncology, 36, 3031-3039. [Google Scholar] [CrossRef] [PubMed]
[14] 朱光海, 李元浩, 高娅雪, 等. 基于“一体两翼, 疏调气机”学说论治恶性肿瘤[J]. 中华中医药杂志, 2020, 35(10): 5046-5049.
[15] 符茗铨, 蒋梅. 基于《黄帝内经》“左升右降”理论的左右半结肠癌的症状及预后差异分析[J]. 时珍国医国药, 2019, 30(11): 2710-2711.
[16] 常兴, 张恬, 隋雨言, 等. 脏腑气机升降理论的渊源探析[J]. 时珍国医国药, 2018, 29(6): 1397-1399.
[17] 余莹, 胡玲. 基于中医思维浅述左、右半结肠癌“两种疾病论” [J]. 中华中医药杂志, 2020, 35(6): 2781-2785.
[18] Qin, Q., Yang, L., Sun, Y., Ying, J., Song, Y., Zhang, W., et al. (2017) Comparison of 627 Patients with Right and Left-Sided Colon Cancer in China: Differences in Clinicopathology, Recurrence, and Survival. Chronic Diseases and Translational Medicine, 3, 51-59. [Google Scholar] [CrossRef] [PubMed]
[19] 刘亚娴. 中西医结合肿瘤病学[M]. 北京: 中国中医药出版社, 2005.
[20] 林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014: 344-352.
[21] 庄振杰. 基于数据挖掘的左右半结肠癌中医遣方用药规律及作用机制研究[D]: [硕士学位论文]. 广州: 广州中医药大学, 2022.
[22] 王馨. 200例结肠癌中医证型分布及相关因素研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2022.
[23] 唐含英. 左右半结肠癌中医证型及相关因素研究[D]: [硕士学位论文]. 南宁: 广西中医药大学, 2018.
[24] 杜薇. 左右半结肠癌术后中医证型与相关因素分析[D]: [硕士学位论文]. 沈阳: 辽宁中医药大学, 2022.
[25] 吴皞. 左右半结直肠癌中医证型及相关因素的对比研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2018.
[26] 何文婷, 张彤, 杨宇飞, 等. 中医药治疗结直肠癌临床疗效Meta分析及证型分析[J]. 中医杂志, 2018, 59(22): 1929-1936.
[27] 戴希勇. 左、右半结肠癌中医证型差异及与微卫星不稳定性的相关研究[D]: [硕士学位论文]. 福州: 福建中医药大学, 2020.
[28] 司富春, 岳静宇. 近30年大肠癌中医证型和用药规律分析[J]. 中华中医药杂志, 2012, 27(7): 1929-1931.
[29] 白姣姣, 阿丽亚·依拉木, 阿布都艾则孜·艾尔肯, 等. 中药复方及单体治疗结肠癌药效与机制研究进展[J]. 中国实验方剂学杂志, 2023, 29(4): 246-252.
[30] 李蒙丽, 严然, 郑川, 等. 基于效应差异探讨中医干预右半结肠癌[J]. 中国中医基础医学杂志, 2018, 24(6): 742-744.
[31] 陈彦臻, 刘沈林. 从“疏肝健脾、益气消癥”论治右半结肠癌[J]. 环球中医药, 2019, 12(9): 1391-1393.